BRAF Inhibitors and IFN aplha: Plus, Minus, or Indeterminate?
Menée in vitro et in vivo, cette étude met en évidence des mécanismes suggérant l'intérêt de combiner un inhibiteur de BRAF et l'interféron alpha pour les patients atteints d'un mélanome présentant la mutation V600E du gène BRAF
In this issue of the Journal, Sabbatino and colleagues evaluate preclinical evidence supporting the hypothesis that BRAF mutant melanoma is associated with interferon alpha (IFN
α) receptor 1 (IFNAR1) downregulation, mediated by increased activity of the βTrCP2/HOS E3 ubiquitin ligase, and consequently decreased sensitivity to antitumor effects of IFNα (1). This in vitro and murine series of studies utilized BRAF-mutant melanoma cell lines, primary/metastatic BRAF mutant human melanoma samples, and tumor xenografts in immunodeficient mice.
..
Journal of the National Cancer Institute , commentaire, 2016